Oric Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Thanks, everyone. So welcome to the final session of the Tuesday morning of the 41st Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the Senior Biotech Analyst here at JPMorgan. I'm joined by Malcolm Kuno and Priyanka Grover from the team.
Our next presenting company is ORIC. And presenting on behalf of the company, we have CEO, Jacob Chacko.
Thank you, Anupam. It's exciting to be in person. It's exciting to get to see folks in real life and get a chance to talk to you about ORIC Pharmaceuticals, which is our company that's developing a pipeline of drugs targeted at cancer resistance. We're quite excited about the way we've built the company, the pipeline that we've built, and I'll get a little bit of time to share that with you today. Of course, I will be making forward-looking statements during the presentation today.
So before I get into the specifics of the pipeline
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
